Molecular Cancer (Oct 2024)

Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development

  • Damien Vasseur,
  • Ludovic Bigot,
  • Kristi Beshiri,
  • Juan Flórez-Arango,
  • Francesco Facchinetti,
  • Antoine Hollebecque,
  • Lambros Tselikas,
  • Mihaela Aldea,
  • Felix Blanc-Durand,
  • Anas Gazzah,
  • David Planchard,
  • Ludovic Lacroix,
  • Noémie Pata-Merci,
  • Catline Nobre,
  • Alice Da Silva,
  • Claudio Nicotra,
  • Maud Ngo-Camus,
  • Floriane Braye,
  • Sergey I. Nikolaev,
  • Stefan Michiels,
  • Gérôme Jules-Clement,
  • Ken André Olaussen,
  • Fabrice André,
  • Jean-Yves Scoazec,
  • Fabrice Barlesi,
  • Santiago Ponce,
  • Jean-Charles Soria,
  • Benjamin Besse,
  • Yohann Loriot,
  • Luc Friboulet

DOI
https://doi.org/10.1186/s12943-024-02134-4
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Background Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments through molecular analysis of fresh tumor biopsies. This report presents the genomic data analysis of the MATCH-R study conducted from 2015 to 2022 and focuses on targeted therapies. Methods The study included resistant metastatic patients (pts) who accepted an image-guided tumor biopsy. After evaluation of tumor content (TC) in frozen tissue biopsies, targeted NGS (10 30%) were performed before and/or after the anticancer therapy. Patient-derived xenografts (PDX) were established by implanting tumor fragments into NOD scid gamma mice and amplified up to five passages. Results A total of 1,120 biopsies were collected from 857 pts with the most frequent tumor types being lung (38.8%), digestive (16.3%) and prostate (14.1%) cancer. Molecular targetable driver were identified in 30.9% (n = 265/857) of the patients, with EGFR (41.5%), FGFR2/3 (15.5%), ALK (11.7%), BRAF (6.8%), and KRAS (5.7%) being the most common altered genes. Furthermore, 66.0% (n = 175/265) had a biopsy at progression on targeted therapy. Among resistant cases, 41.1% (n = 72/175) had no identified molecular mechanism, 32.0% (n = 56/175) showed on-target resistance, and 25.1% (n = 44/175) exhibited a by-pass resistance mechanism. Molecular profiling of the 44 patients with by-pass resistance identified 51 variants, with KRAS (13.7%), PIK3CA (11.8%), PTEN (11.8%), NF2 (7.8%), AKT1 (5.9%), and NF1 (5.9%) being the most altered genes. Treatment was tailored for 45% of the patients with a resistance mechanism identified leading to an 11 months median extension of clinical benefit. A total of 341 biopsies were implanted in mice, successfully establishing 136 PDX models achieving a 39.9% success rate. PDX models are available for EGFR (n = 31), FGFR2/3 (n = 26), KRAS (n = 18), ALK (n = 16), BRAF (n = 6) and NTRK (n = 2) driven cancers. These models closely recapitulate the biology of the original tumors in term of molecular alterations and pharmacological status, and served as valuable models to validate overcoming treatment strategies. Conclusion The MATCH-R study highlights the feasibility of on purpose image guided tumor biopsies and PDX establishment to characterize resistance mechanisms and guide personalized therapies to improve outcomes in pre-treated metastatic patients. Graphical Abstract

Keywords